Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: 777 Captain who wrote (19073)	2/25/1999 8:36:00 AM
From: RT	Read Replies (2) \| Respond to of 23519

MOUNTAIN VIEW, Calif.--(BW HealthWire)--Feb. 25, 1999--VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company has received notification that the license necessary for the launch of MUSE(R) (alprostadil) in Germany has been granted. This license triggers a $2 million milestone payment to VIVUS from ASTRA. Several additional European Union countries have recently issued licenses for MUSE, including Denmark, The Netherlands, Ireland, Luxembourg and Finland. Currently, ASTRA is planning to launch MUSE in these countries during the second quarter of 1999. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS, Inc., Mountain View Nina W. Ferrari, 650/934-5200 (Director, Corp. Comm.) IR@VIVUS.com